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Abstract 
We present the case of a 51-year-old male patient who received adjuvant chemotherapy 
consisting of oxaliplatin, bolus and continuous 5-fluorouracil (5-FU) and leucovorin after 
anterior resection because of locally advanced rectal cancer. Preoperative chemotherapy 
with capecitabine (an oral 5-FU prodrug) had been well tolerated. Two days after initiation 
of the first course of chemotherapy, the patient reported typical chest pain. The ECG showed 
ST elevations and prominent T waves in almost all leads. Due to suspicion of a high-risk acute 
coronary syndrome, an urgent cardiac catheterization was performed. It showed a generally 
reduced coronary flow with multiple significant stenoses (including the ostia of the left and 
right coronary artery), as well as a highly reduced left ventricular function with diffuse 
hypokinesia. Due to the meanwhile completely stable situation of the patient after medical 
acute coronary syndrome treatment, no ad hoc intervention was performed to allow further 
discussion of the optimal management. Thereafter, the patient remained clinically 
asymptomatic, without any rise in cardiac necrosis parameters; only NT-pro-BNP was 
significantly elevated. A control cardiac catheterization 2 days later revealed a restored 
normal coronary artery flow with only coronary calcifications without significant stenoses, as 
well as a normal left ventricular ejection fraction. Cardiovascular symptoms occurred on the 
second day of continuous 5-FU treatment. As cardiotoxic effects seem to appear more 
frequently under continuous application of 5-FU, compared to the earlier established 5-FU 
bolus regimens, treating medical oncologists should pay special attention to occurring  
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cardiac symptoms and immediately interrupt 5-FU chemotherapy and start a cardiologic 
work-up. 
 
Introduction 
The cytostatic drug 5-fluorouracil (5-FU) is used for the treatment of malignant 
tumors of the gastrointestinal tract, the head and neck region as well as breast cancers. 
For development of 5-FU cardiotoxicity, several different causative mechanisms like 
occurrence of coronary artery spasm [1], direct non-ischemic toxic effects on 
myocardial cells [2], endothelial damage [3], or decreased oxygen concentrations in the 
blood [4] are considered. Cardiotoxic effects are also described for capecitabine, an oral 
5-FU prodrug [5]. 
We report a case of acute transient heart failure caused by 5-FU-induced general 
coronary vasoconstriction while the patient was still under continuous infusion of 5-FU 
in combination with leucovorin and oxaliplatin during the second day of administration 
of the drug.  
Case Report 
A 51-year-old male patient with locally advanced rectal cancer and status post-anterior resection 
of the rectum and post-preoperative chemoradiation with capecitabine postoperatively received 
adjuvant combination chemotherapy consisting of oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, and 
5-FU (400 mg/m2 bolus i.v. followed by 2,400 mg/m2 continuous infusion over 48 h i.v.) 
corresponding to modified FOLFOX 6 schedule on an outpatient basis. 
In his medical history, no cardiac events had been reported, but a high cardiovascular risk profile 
was present with arterial hypertension, hyperlipidemia, current cigarette smoking (80 pack-years), 
and known peripheral artery disease. On the second day of the continuous 5-FU infusion, the patient 
reported typical chest pain. The ECG (fig. 1) showed significant ST elevations and prominent T waves 
in almost all leads (I–III, aVF, and V2–V6); blood pressure was normal with 130/70 mm Hg. After 
starting acute coronary syndrome therapy (including platelet function inhibition with prasugrel and 
acetylsalicylic acid), the ECG returned to normal and the clinical symptoms improved. However, due 
to the significant dynamic ST changes, an acute coronary angiography was performed. It revealed a 
generally reduced coronary flow (TIMI II–III), with an ostial stenosis of the left main coronary artery, 
multiple focal stenoses in the circumflex artery, the left anterior descending coronary artery and the 
diagonal branch (fig. 2a), and an ostial stenosis of the right coronary artery. Left ventricular ejection 
fraction (LVEF) was highly reduced (24%) with diffuse hypokinesia (fig. 2b) and a highly elevated left 
ventricular end-diastolic filling pressure (LVEDP) of 30 mm Hg. Due to the already normalized ECG 
and since the patient was meanwhile asymptomatic, no ad hoc intervention was performed to allow 
further interdisciplinary discussion of optimal further management. During the following days, 
cardiac necrosis parameters remained negative, only NT-pro-BNP plasma level was significantly 
elevated (2,960 pg/ml). A medical therapy with an ACE inhibitor, diuretics, and a calcium channel 
blocker was established. Echocardiographic follow-up 2 days later surprisingly showed a marked 
improvement of left ventricular function (LVEF approximately 50–55%). Follow-up angiography 2 
days after first angiography showed a normal coronary flow (TIMI III) and coronary calcifications 
without significant stenoses (fig. 3a). LVEF with 60% was also normal (fig. 3b) and LVEDP with 16 
mm Hg was only marginally elevated. The patient could be discharged in good clinical condition with 
oral medication including acetylsalicylic acid, verapamil, and atorvastatin. At follow-up after 5 
months, a normal NT-pro-BNP was recorded (96.95 pg/ml), and the patient remained free of further 
cardiac symptoms.  
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Discussion 
To our knowledge, this case report represents the first detailed documentation of 
the potentially life-threatening complication of generalized coronary vasoconstriction 
in combination with acute transient heart failure and its reversibility in connection 
with adjuvant chemotherapy consisting of 5-FU (bolus and continuous), leucovorin, and 
oxaliplatin.  
Concerning the 5-FU plasma levels achieved while administering the bolus and 
continuous 5-FU schedule (also called FOLFOX schedule), 5-FU steady-state plasma 
levels on the first and second day of treatment of about 340 ng/ml are observed [6]. 
These 5-FU plasma levels correspond to the 5-FU plasma levels of ~30 ng/ml and 900 
ng/ml, respectively, reached when capecitabine is delivered at 1,250 mg/m2 [7, 8] and 
at 825 mg/m2 [9], the meanwhile established standard for chemoradiation [10], which 
was used in the case presented. 5-FU maximal plasma levels reached by bolus 
injections exceed by 100-fold the maximal concentration of 5-FU metabolized from 
capecitabine or continuous 5-FU infusions plus leucovorin [6]. Therefore, presumably, 
maximal peak concentrations of 5-FU levels do not play the key role in producing 5-FU-
triggered toxicity. 
According to Kosmas et al. [11], 5-FU toxicity is a schedule-dependent event, 
resulting in higher toxicity of 6.7% on continuous infusion compared to short-term 5-
FU infusion (2.3%). In addition to continuous 5-FU, the application of leucovorin 
contributes to increased cardiotoxicity [11]. 
Theoretically, administration of oxaliplatin which preceded administration of 5-FU 
might have had an independent or an additional effect on the coronary vessels. 
Although a pharmacologic drug interaction between oxaliplatin and 5-FU may not be 
completely excluded, the occurrence of a pharmacokinetic drug-drug interaction seems 
unlikely [12]. 
It is noteworthy that our patient tolerated oral intake of capecitabine, an oral 5-FU 
prodrug, for 5 weeks during preoperative chemoradiation without occurrence of 
clinically symptomatic coronary vasoconstriction. In our opinion, this phenomenon 
remains unexplained and is in contrast with the observation made by Shaib et al. [13]. 
They reported a patient with repeated cardiotoxic symptoms following administration 
of either capecitabine or continuous 5-FU in form of the FOLFOX (5-FU, oxaliplatin, and 
leucovorin) regimen but not following bolus 5-FU intravenously, as used in the FLOX 
regimen (5-FU, leucovorin, and oxaliplatin) [13]. To speculate, individual disposition, 
environmental influences, or medication interactions may have played a role in our 
patient who developed cardiac toxicity on exposition to modified FOLFOX 6 schedule 
but not on capecitabine. However, once patients have experienced cardiac toxicity 
caused by 5-FU, they should not be rechallenged as the risk of recurrence of 
cardiotoxicity is known to be high [14]. 
In summary, our case report shows that 5-FU infusion (bolus and continuous) 
combined with leucovorin and oxaliplatin is able to induce coronary vasoconstriction 
leading to acute but reversible heart failure. Cardiovascular symptoms due to 5-FU 
toxicity occurred typically on day 2 of the first cycle of chemotherapy [15]. Cardiotoxic 
events caused by continuous application of 5-FU seem to appear more frequently  
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compared to the historically administered 5-FU bolus regimens. In case cardiac 
symptoms occur, the treating medical oncologists should immediately interrupt the 5-
FU-containing (poly)chemotherapy and start a cardiologic work-up. Rechallenge with 
5-FU is not recommended. Pursuing this strategy, reversion of cardiotoxicity is possible 
as shown in our case. Previous symptomless tolerance of capecitabine does not 
preclude occurrence of toxicity by 5-FU (bolus and continuous) administration in 
combination with leucovorin and oxaliplatin. 
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Fig. 1. ECG with ST elevations and prominent T waves (I–III, aVF, and in V2–V6). 
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Fig. 2. Acute cardiac catheterization. a Caudal RAO projection of the left coronary artery, with ostial 
left main stenosis (bold arrow), mid circumflex artery stenosis (normal arrow), and diffuse calcified 
left anterior descending artery stenosis (small arrows). b Ventriculography (RAO 30°). Quantitative 
evaluation revealed a highly reduced left ventricular function (LVEF 24%) with diffuse hypokinesia 
and highly elevated LVEDP of 30 mm Hg.  
 
 
 
Fig. 3. Control cardiac catheterization 2 days later. a Caudal RAO projection of the left coronary artery: 
normalized left main (bold arrow) and non-significant circumflex artery stenosis (normal arrow), 
diffusely non-significantly diseased left anterior descending artery (small arrows). b Ventriculography 
(RAO 30°). Quantitative evaluation revealed a normal left ventricular function (LVEF 60%) and no 
wall motion abnormalities, with near normal LVEDP of 16 mm Hg. 
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